The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”
Category: Pallone, Frank Jr
-
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen
The New York Times – Business:
